ArticleESC heart failure2023
Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.
Article in ESC heart failure, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Identification of signal-based gait features and blood analytes associated with stroke status and walking speed in mild acute ischemic stroke.BMC neurology · 2026Article
- Frailty prediction in heart failure patients with acute infections: the potential role of thiazide diuretics?PloS one · 2026Article
- Development and validation of a nomogram for predicting prolonged intensive care unit stay in patients with acute myocardial infarction and analysis of associated hospitalization costs.Frontiers in cardiovascular medicine · 2026Article
- Heart Failure in the Modern Era: A Narrative Overview of Recent Research from 2022-2025.Journal of cardiovascular development and disease · 2025Review
- Association between mean corpuscular hemoglobin concentration and mortality in ICU patients with acute kidney injury: a retrospective multicenter cohort study.European journal of medical research · 2025Article
- Biomarkers in heart failure: Traditional and emerging indicators for prognosis.ESC heart failure · 2025Article
- Predictive biosignatures for hospitalization in patients with virologically confirmed COVID-19.Journal of the Chinese Medical Association : JCMA · 2025Article
- Red Blood Cell-Related Phenotype-Genotype Correlations in Chronic and Acute Critical Illnesses (Traumatic Brain Injury Cohort and COVID-19 Cohort).International journal of molecular sciences · 2025Article
- Mendelian randomization study highlights the role of hematological traits on Type-2 diabetes mellitus in African ancestry individuals.Frontiers in pharmacology · 2025Article
- Clustering Based on Laboratory Data in Patients With Heart Failure Admitted to the Intensive Care Unit.Journal of clinical laboratory analysis · 2024Article
- The Effect of Four-Month Training on Biochemical Variables in Amateur Cross-Country Skiers.Journal of clinical medicine · 2024Article
- Unraveling the Impact of COVID-19 on Rheumatoid Arthritis: Insights from Two Romanian Hospitals-Preliminary Results.Biomedicines · 2024Article
- Evaluation of Pro-BNP biomarker in heart failure patients and its relationship with complete blood count parameters: A case-control study.Health science reports · 2024Article
- Iron-related Biomarkers in the Diagnosis and Management of Iron Disorders.Current medicinal chemistry · 2024Review
- Article
- Mean corpuscular haemoglobin concentration and outcomes in heart failure with preserved ejection fraction.ESC heart failure · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
aimsThis study aims to evaluate the prognostic value of mean corpuscular haemoglobin concentration (MCHC) on clinical outcomes in patients with heart failure with preserved ejection fraction (HFpEF). METHODS AND
resultsWe analysed HFpEF participants from the Americas in the Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone Antagonist (TOPCAT) trial with available baseline data (n = 1747). Patients were grouped into hypochromia or non-hypochromia group according to a MCHC cut-off level of 330 g/L. Cox proportional hazard model was used to explore the prognostic value of hypochromia on the long-term clinical outcomes (the primary endpoint [composite of cardiovascular mortality, HF hospitalization and aborted cardiac arrest], any-cause and HF hospitalization, all-cause and cardiovascular mortality). Patients were further stratified according to baseline estimated glomerular filtration rate (eGFR) to explore the impact of renal dysfunction on the prognostic value of hypochromia. Baseline hypochromia was prevalent (n = 662, 37.9%) and strongly associated with worse clinical outcomes. In patients with worse renal function (eGFR < 60 mL/min per 1.73 m
conclusionsAmong HFpEF patients, hypochromia (i.e. MCHC ≤ 330 g/L) is independently associated with adverse clinical outcomes, especially when in the presence of co-morbidity renal dysfunction.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.